CG
CTIC

Cutler Group’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Cutler Group’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8,100
Closed -$9K – 5873
2022
Q2 		$9K Sell
8,100
-27,000
-77% -$138K ﹤0.01% 3333
2022
Q1 		$46K Buy
+35,100
New +$105K ﹤0.01% 2328

Other funds holding CTIC

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Cutler Group's CTIC Position: Q4 2022 in Review

Cutler Group sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2022, closing a stake of 540 shares — an estimated $2.95K sold.

Cutler Group first reported a position in CTIC in Q4 2015 and held it in 9 quarters. The position peaked at $126K in Q1 2022. 145 funds tracked by Wall St. Rank hold CTIC as of Q4 2022.

  • Cutler Group reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2022 after selling out during the quarter.
  • Cutler Group sold 540 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2022, an estimated $2.95K.
  • Cutler Group first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2015 and held it in 9 quarters.
  • Cutler Group's CTI BioPharma Corp. (DE) Common Stock position peaked at $126K in Q1 2022.
  • 145 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2022.

Based on Cutler Group's 13F filing for Q4 2022, filed 7 Feb 2023.